FY2024 Earnings Forecast for CKPT Issued By HC Wainwright

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Checkpoint Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.94) for the year, down from their prior forecast of ($0.80). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Checkpoint Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Checkpoint Therapeutics’ Q4 2024 earnings at ($0.22) EPS.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08).

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock opened at $3.43 on Monday. The stock has a market capitalization of $154.42 million, a P/E ratio of -1.86 and a beta of 1.23. The company’s fifty day moving average price is $2.82 and its 200 day moving average price is $2.35. Checkpoint Therapeutics has a 1 year low of $1.36 and a 1 year high of $3.97.

Institutional Trading of Checkpoint Therapeutics

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in Checkpoint Therapeutics in the 2nd quarter valued at about $34,000. Gladstone Institutional Advisory LLC lifted its position in shares of Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares in the last quarter. Magnus Financial Group LLC boosted its stake in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after acquiring an additional 4,000 shares during the last quarter. 180 Wealth Advisors LLC purchased a new stake in shares of Checkpoint Therapeutics during the second quarter worth approximately $96,000. Finally, Choreo LLC raised its stake in Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.